3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Interventions
pembrolizumab
37
Paclitaxel
36
Carboplatin
31
Cyclophosphamide
22
Albumin-Bound Paclitaxel
20
atezolizumab
16
130-nm albumin-bound paclitaxel
16
Taxes
15
Doxorubicin
15
Cisplatin
13
Capecitabine
13
Nivolumab
10
Docetaxel
8
olaparib
7
Gemcitabine
6
Everolimus
6
talazoparib
5
durvalumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Bevacizumab
5
veliparib
4
spartalizumab
4
sacituzumab govitecan
4
pegfilgrastim
4
liposomal doxorubicin
4
eribulin
4
Specimen Handling
4
Immunoglobulin G
4
trilaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Triple Negative Breast Neoplasms
×
Anthracyclines
×
Clear all
NCT02622074
2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1
Completed
60 enrolled
26 charts